Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).

[1] It is photoactivated by 732 nm light which allows greater depth of penetration.

[2] Phase II clinical trials were in progress in 1999.